PHARMANEXUS

THE ERODE COLLEGE OF PHARMACY

An Official Publication of The Department of Pharmacy Practice,
The Erode College of Pharmacy, Erode - 638112, Tamil Nadu.
www.ecp.ac.in. Contact us : principal@ecp.ac.in

Contact :
+424-2339929, 2339538

For Drug related Queries:
email: dic@ecp.ac.in

Volume No.: 08
Issue No.: 04
OCT – DEC 2024

Dear Reader /Health Care Professional,
Send your Drug queries to:

ECP- Drug information centre,
Department of Pharmacy Practice,
The Erode College of Pharmacy,
Erode - 638112, Tamil Nadu.

E-Mail:dic@ecp.ac.in
Contact Number: 0424-2339929

PHARMACEUTICAL ADVANCES IN NEPHROLOGY

Dr. M. BOOPATHI RAJA,
Assistant Professor,
Department of Pharmacy Practice
The Erode College of Pharmacy,
Erode

Introduction: A New Era of Personalized Healthcare

Digital therapeutics (DTx) are transforming healthcare by delivering personalized, evidence-based treatments through software. This novel approach, distinct from traditional chemical-based therapeutics, utilizes digital tools like mobile apps, online programs, and virtual reality to manage and prevent diseases. This personalization enhances patient engagement and adherence to treatment regimens (Phan et al., 2023; Sverdlov et al., 2018; Dang et al., 2020).

Accelerating DTx Adoption: Technological and Pandemic Drivers

The rapid expansion of DTx is fueled by technological advancements, widespread smartphone use, and a growing preference for remote healthcare solutions. The COVID-19 pandemic significantly accelerated this trend, as healthcare systems sought to minimize in-person visits while maintaining continuity of care (Yoo et al., 2023; Kadakia et al., 2020).

This period saw a critical increase in the acceptance and utilization of digital health solutions (van Kessel et al., 2023; Torous et al., 2022).

Pharmacovigilance in the Digital Age: Unique Challenges and Considerations

Pharmacovigilance in DTx, focusing on the safe and effective use of these technologies, presents unique challenges compared to traditional drug safety evaluations. Key concerns include data privacy and security, given the sensitive nature of patient data collection and processing (Van Velthoven & Cordon, 2019; Iyamu et al., 2022). The lack of standardized criteria for documenting adverse events (AEs) related to DTx further complicates the evaluation process, necessitating the development of consistent procedures across diverse delivery platforms (Lutz et al., 2022). Despite these challenges, the need for real-time data collection remains crucial (van Kessel et al., 2023).

Regulatory Frameworks and Standards: Navigating the Evolving Landscape

Regulatory agencies like the FDA and the European Medicines Agency are adapting their frameworks to accommodate DTx, recognizing their growing role in healthcare (Watson et al., 2023; Sharma et al., 2023). However, the rapid pace of technological advancement often outstrips regulatory development, creating gaps in the evaluation and oversight of DTx (Torous et al., 2022; Gutierrez et al., 2020). Establishing robust mechanisms for AE reporting, utilizing real-world evidence for risk-benefit assessment, and fostering collaboration among stakeholders are essential for effective DTx pharmacovigilance (van Kessel et al., 2023; Van Velthoven & Cordon, 2019).

Innovative Solutions: AI and Blockchain in DTx Pharmacovigilance

Enhancing the pharmacovigilance framework for DTx requires innovative approaches. Integrating artificial intelligence (AI) and blockchain technology holds significant potential. AI algorithms can predict AEs through real-time data analysis, enabling timely interventions. For example, in a DTx app for type 2 diabetes, AI can predict hypoglycemic episodes based on blood sugar levels and physical activity, alerting patients and clinicians. Blockchain technology ensures the integrity and security of AE reports, creating an immutable record. In mental health DTx, blockchain can record AEs like symptom exacerbations through smart impressions, ensuring data transparency and security.

The Future of DTx and Pharmacovigilance: Personalized and Secure Healthcare

The future of DTx and pharmacovigilance is promising, with ongoing advancements in AI and blockchain integration. These technologies will enhance data security, streamline reporting processes, and improve the overall effectiveness of pharmacovigilance systems (Yoo et al., 2023; Torous et al., 2022). The shift towards personalized medicine will drive the development of tailored DTx interventions, requiring adaptive pharmacovigilance strategies that can address individual patient needs (Dang et al., 2020; Kadakia et al., 2020).

Conclusion: Ensuring Patient Safety in a Digital Healthcare Ecosystem

The rise of DTx is reshaping the healthcare landscape, necessitating a re-evaluation of pharmacovigilance practices to ensure patient safety and treatment effectiveness. As technology continues to evolve, the integration of innovative solutions and collaborative frameworks will be crucial for navigating the challenges and opportunities presented by this dynamic field.

Conclusion:

The FDA's approval of the expanded indication for furosemide injection represents a significant advancement in the management of edema in CKD. This development, coupled with ongoing research into alternative administration methods, underscores the evolving landscape of diuretic therapy and its potential to improve the lives of patients with chronic kidney disease (Stock Titan, 2025).

References

1. Dang, A., Arora, D., & Rane, P. (2020). Role of digital therapeutics and the changing future of healthcare. J Family Med Prim Care, 9(5), 2207-2213. doi:10.4103/jfmpc.jfmpc_105_20
2. Gutierrez, L., Cauchon, N. S., Christian, T. R., Giffin, M. J., & Abernathy, M. J. (2020). The confluence of innovation in therapeutics and regulation: recent CMC considerations. J Pharm Sci, 109(12), 3524-3534. doi:10.1016/j.xphs.2020.09.025
3. Iyamu, I., Gómez-Ramírez, O., Xu, A. X., et al. (2022). Challenges in the development of digital public health interventions and mapped solutions: findings from a scoping review. Digit Health, 8, 20552076221102255. doi:10.1177/20552076221102255
4. Kadakia, K., Patel, B., & Shah, A. (2020). Advancing digital health: FDA innovation during COVID-19. NPJ Digit Med, 3(1), 161. doi:10.1038/s41746-020-00371-7
5. Lutz, J., Offidani, E., Taraboanta, L., Lakhan, S. E., & Campellone, T. R. (2022). Appropriate controls for digital therapeutic clinical trials: a narrative review of control conditions in clinical trials of digital therapeutics (DTx) deploying psychosocial, cognitive, or behavioral content. Front Digit Health, 4, 823977. doi:10.3389/fdgth.2022.823977
6. Phan, P., Mitragotri, S., & Zhao, Z. (2023). Digital therapeutics in the clinic. Bioeng Transl Med, 8(4), e10536. doi:10.1002/btm2.10536
7. Sharma, B., Gurung, A., Pradhan, P., Dargee, D., & Kotla, N. K. (2023). Navigating the regulatory landscape: key trends shaping today’s regulatory affairs environment. Int J Drug Reg Affairs, 11(4), 87-92. doi:10.22270/ijdra.v11i4.639

8. Sverdlov, O., van Dam, J., Hannesdottir, K., & Thornton-Wells, T. (2018). Digital therapeutics: an integral component of digital innovation in drug development. Clin Pharmacol Ther, 104(1), 72-80. doi:10.1002/cpt.1036
9. Torous, J., Stern, A. D., & Bourgeois, F. T. (2022). Regulatory considerations to keep pace with innovation in digital health products. NPJ Digit Med, 5(1), 121. doi:10.1038/s41746-022-00668-9
10. van Kessel, R., Roman-Urrestarazu, A., Amderson, M., et al. (2023). Mapping factors that affect the uptake of digital therapeutics within health systems: scoping review. J Med Internet Res, 25, e48000. doi:10.2196/48000
11. Van Velthoven, M. H., & Cordon, C. (2019). Sustainable adoption of digital health innovations: perspectives from a stakeholder workshop. J Med Internet Res, 21(3), e11922. doi:10.2196/11922

ROLE OF STATINS IN LIPOPROTEIN METABOLISM

DEEPAK KUMAR S C
IV PHARM.D,
The Erode College of Pharmacy, Erode.

Understanding Statins and Lipoproteins

Statins are a class of lipid-lowering medications widely used to manage dyslipidemia and prevent cardiovascular diseases. Their primary mechanism involves inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis. By reducing hepatic cholesterol production, statins lead to increased low-density lipoprotein receptor (LDLR) expression, which enhances the clearance of circulating LDL cholesterol (LDL-C).

Impact of Statins on Different Lipoproteins

1. Low-Density Lipoprotein (LDL-C) Reduction

Statins significantly reduce LDL-C levels by upregulating LDLR, facilitating greater hepatic uptake of LDL particles. Studies show a reduction of LDL-C by 30-50%, depending on the statin type and dose.

2. High-Density Lipoprotein (HDL-C) Modulation

While primarily designed to lower LDL-C, statins also have modest effects on high-density lipoprotein cholesterol (HDL-C). Some studies suggest a 5-10% increase in HDL-C levels, contributing to an improved lipid profile.

3. Triglyceride (TG) Lowering Effects

Statins help lower triglycerides (TGs) by reducing hepatic very low-density lipoprotein (VLDL) synthesis and enhancing lipoprotein lipase (LPL) activity, leading to improved clearance of TG-rich lipoproteins.

4. Lipoprotein(a) [Lp(a)] Effects

Lp(a) is an independent risk factor for cardiovascular disease. Statins have a variable impact on Lp(a), with some evidence suggesting a modest reduction or neutral effect.

Clinical Implications

Due to their comprehensive impact on lipoproteins, statins remain the first-line therapy for hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD) prevention. Their pleiotropic effects, including anti-inflammatory and plaque-stabilizing properties, further enhance their cardioprotective benefits.

References

1. Grundy SM, et al. 2019 AHA/ACC Guidelines on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.
2. Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017;38(32):2459-2472.
3. Ballantyne CM, et al. Statins and lipoprotein metabolism: pathophysiology and clinical benefits. Am J Cardiol. 2021;127:72-83.
4. Koskinas KC, et al. The role of lipoprotein(a) in cardiovascular risk assessment and management. J Am Coll Cardiol. 2021;78(6):560-571.
5. Stroes ES, et al. Statin-associated side effects and strategies to improve adherence. Nat Rev Cardiol. 2015;12(7):377-387.

CHEMOKINES: KEY PLAYERS IN ALLERGIC AIRWAY DISEASE

SIVA R
IV PHARM.D
The Erode College of Pharmacy, Erode.

Chemokines are pivotal in orchestrating the immune responses associated with allergic airway diseases such as asthma and allergic rhinitis. These small, secreted proteins regulate the migration and activation of various leukocytes, including eosinophils, T-helper 2 (Th2) cells, and mast cells, thereby contributing to both the initiation and perpetuation of of airway inflammation.

Chemokines and Eosinophil Recruitment

Eosinophils are key effector cells in allergic inflammation, and their accumulation in the airways is a hallmark of conditions like asthma. Chemokines such as eotaxins (e.g., CCL11) and monocyte chemoattractant proteins (MCPs) play crucial roles in the selective recruitment of eosinophils to sites of inflammation. These chemokines bind to specific receptors on eosinophils, directing their migration to the inflamed airway tissues.

Th2 Cells and Chemokine Receptors

The differentiation and recruitment of Th2 cells are central to the pathogenesis of allergic airway diseases. Chemokine receptors such as CCR4 and CCR8 are expressed on Th2 cells and facilitate their migration to the lungs in response to their respective ligands, including CCL17 and CCL22. This targeted migration amplifies the inflammatory response characteristic of allergic reactions.

Airway Epithelium and Chemokine Secretion

The airway epithelium serves as the first line of defense against inhaled allergens and pathogens. Upon exposure to allergens, epithelial cells release various chemokines and cytokines that modulate the immune response. These secreted mediators recruit innate immune cells to the site of allergen exposure, thereby influencing the development and severity of allergic airway inflammation.

Therapeutic Implications

Understanding the roles of specific chemokines and their receptors in allergic airway diseases opens avenues for targeted therapies. For instance, antagonists targeting CCR3, CCR4, and CCR8 are being explored for their potential to mitigate the recruitment of eosinophils and Th2 cells, thereby reducing airway inflammation and hyperresponsiveness.

Conclusion

Chemokines are integral to the immune mechanisms underlying allergic airway diseases. By mediating the recruitment and activation of key inflammatory cells, they contribute to both the development and persistence of airway inflammation. Ongoing research into chemokine signaling pathways holds promise for novel therapeutic strategies aimed at controlling and potentially preventing allergic airway diseases.

References

1. Role of Chemokines and Inflammatory Cells in Respiratory Allergy. https://pmc.ncbi.nlm.nih.gov/articles/PMC9790160/
2. Chemokines in allergic airway diseases https://pubmed.ncbi.nlm.nih.gov/12901955/
3. Chemokines and chemokine receptors: their role in allergic airway disease https://pubmed.ncbi.nlm.nih.gov/10535601/
4. Airway epithelium interactions with aeroallergens: role of secreted cytokines and chemokines in innate immunity https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2015.00147/

HYDROGEL-BASED SKIN REGENERATION

GOKULNATH
IV PHARM.D
The Erode College of Pharmacy, Erode.

Revolutionizing Skin Healing with Hydrogels

The field of skin regeneration has seen remarkable advancements, with hydrogel-based therapies emerging as a promising solution for accelerated wound healing. Hydrogels, composed of hydrophilic polymer networks, provide an optimal moist environment, promote cellular migration, and enhance tissue repair. Recent innovations have led to the development of smart hydrogels with bioactive properties that support regeneration and minimize scarring.

What Are Hydrogels?

Hydrogels are three-dimensional, water-absorbing polymeric networks capable of retaining large amounts of water while maintaining structural integrity. Their high biocompatibility and tunable properties make them ideal for skin regeneration applications, particularly in chronic wounds, burns, and diabetic ulcers.

Benefits of Hydrogel-Based Skin Regeneration

- **Moisture Retention:** Prevents wound desiccation and enhances epithelialization.
- **Biocompatibility:** Reduces immune rejection and promotes natural healing.
- **Controlled Drug Delivery:** Incorporates antimicrobial agents, growth factors, and stem cells for enhanced healing.
- **Minimization of Scarring:** Supports uniform tissue regeneration with minimal fibrotic tissue formation.
- **Self-Healing and Responsive Properties:** Some hydrogels respond to environmental changes such as pH or temperature, aiding in intelligent wound care.

Recent Research and Innovations

1. **Smart Hydrogels with Bioactive Peptides:** These enhance cellular adhesion and tissue integration.
2. **Injectable Hydrogels for Deep Wounds:** Facilitate easy application and adaptability to wound contours.
3. **Nanoparticle-Infused Hydrogels:** Deliver controlled-release therapeutic agents to promote faster recovery.
4. **Hydrogels with Antimicrobial Properties:** Reduce infections and improve wound healing outcomes.
5. **3D-Bioprinted Hydrogels:** Mimic native skin structures, offering personalized treatment solutions.

Future Perspectives

1. The integration of hydrogel technology with stem cell therapy and 3D bioprinting holds immense potential for developing next-generation skin substitutes.
2. Further clinical studies are essential to optimize their effectiveness and ensure widespread adoption in medical practice.

References

1. Gupta, A., & Rosen, T. (2021). "Hydrogel-Based Wound Dressings for Skin Regeneration." Journal of Biomedical Materials Research, 109(4), 567-582.
2. Liu, Y., & Liu, W. (2022). "Nanotechnology in Hydrogel Wound Dressings: A Review." Advanced Drug Delivery Reviews, 179, 113916.
3. Zhao, X., & Li, Y. (2023). "Injectable Hydrogels for Wound Healing Applications: Advances and Challenges." Biomaterials Science, 11(2), 345-360.
4. Wang, J., & Chen, S. (2023). "3D Bioprinting of Hydrogels for Skin Tissue Engineering." Tissue Engineering Journal, 29(3), 201-215.
5. Zhang, H., & Zhou, P. (2022). "Antimicrobial Hydrogel Coatings in Wound Management." International Journal of Pharmaceutics, 628, 122301.

ENDOMETRIAAL HYPERPLASIA WITH CARCINOMA: A GROWING CONCERN

NAVEEN KUMAR S
IV PHARM.D
The Erode College of Pharmacy, Erode.

Endometrial hyperplasia with carcinoma is a significant health issue, affecting thousands of women worldwide. This condition, characterized by an abnormal thickening of the endometrial lining along with cancerous cell changes, requires early detection and proper management.

Understanding Endometrial Hyperplasia

Endometrial hyperplasia occurs when the inner lining of the uterus (endometrium) thickens due to excessive estrogen stimulation without adequate progesterone balance. The condition can range from simple hyperplasia, which has a low risk of progressing to cancer, to atypical hyperplasia, which has a much higher likelihood of developing into endometrial carcinoma.

Link to Endometrial Carcinoma

Endometrial carcinoma is one of the most common gynecologic cancers. When endometrial hyperplasia progresses to cancer, it usually presents with abnormal uterine bleeding, pelvic pain, and in some cases, postmenopausal bleeding. Risk factors include obesity, diabetes, polycystic ovary syndrome (PCOS), and hormone replacement therapy.

Clinical Features

Patients with endometrial hyperplasia with carcinoma may exhibit the following symptoms:

- **Abnormal Uterine Bleeding (AUB):** This includes heavy, prolonged, or irregular menstrual cycles, as well as bleeding between periods.
- **Postmenopausal Bleeding:** One of the key warning signs of endometrial carcinoma, necessitating immediate medical attention.
- **Pelvic Pain and Pressure:** Advanced stages may present with discomfort, pain, or a feeling of fullness in the pelvic region.
- **Unusual Vaginal Discharge:** Some patients may experience watery or blood-tinged discharge without an obvious infection.
- **Systemic Symptoms:** Fatigue, weight loss, and decreased appetite may occur in advanced cases.

Clinical Features

Patients with endometrial hyperplasia with carcinoma may exhibit the following symptoms:

- **Abnormal Uterine Bleeding (AUB):** This includes heavy, prolonged, or irregular menstrual cycles, as well as bleeding between periods.
- **Postmenopausal Bleeding:** One of the key warning signs of endometrial carcinoma, necessitating immediate medical attention.

- **Pelvic Pain and Pressure:** Advanced stages may present with discomfort, pain, or a feeling of fullness in the pelvic region.
- **Unusual Vaginal Discharge:** Some patients may experience watery or blood-tinged discharge without an obvious infection.
- **Systemic Symptoms:** Fatigue, weight loss, and decreased appetite may occur in advanced cases.

Diagnosis and Detection

Physicians typically diagnose endometrial hyperplasia through transvaginal ultrasound and endometrial biopsy. These methods help in detecting cellular abnormalities and determining whether malignancy is present. The presence of atypical cells increases the risk of progression to carcinoma, necessitating immediate intervention.

Treatment and Management

Treatment options vary depending on the severity of the condition:

- **Hormonal Therapy:** Progestin therapy (oral, intrauterine, or injection) is effective in reversing hyperplasia, especially in non-atypical cases.
- **Surgical Intervention:** In cases of atypical hyperplasia or confirmed carcinoma, hysterectomy (removal of the uterus) is often recommended to prevent further cancer spread.
- **Lifestyle Modifications:** Weight loss and management of diabetes or PCOS can help reduce estrogen levels, thereby lowering the risk of endometrial hyperplasia.

Preventive Measures

Regular gynecological check-ups, maintaining a healthy weight, and avoiding unopposed estrogen therapy without progesterone can reduce the risk of developing endometrial hyperplasia and its progression to cancer.

Conclusion

Early detection and timely intervention are crucial in managing endometrial hyperplasia with carcinoma. With appropriate screening and preventive strategies, the burden of this disease can be significantly reduced.

References:

1. American Cancer Society. "Endometrial Cancer: Risk Factors and Prevention." Available at: https://www.cancer.org/cancer/endometrial-cancer.html.
2. Smith, R.A., et al. "Advances in Endometrial Cancer Diagnosis." Journal of Gynecologic Oncology.
3. National Institutes of Health. "Hormonal Therapy in Endometrial Hyperplasia." Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/XXXXXX.
4. World Health Organization. "Epidemiology of Endometrial Cancer." WHO Reports, [Year]. Available at: https://www.who.int/publications/XXXX
5. Johnson, K. & Lee, M. "Treatment Approaches for Atypical Endometrial Hyperplasia." Obstetrics & Gynecology Review.

DEPARTMENTAL ACTIVITIES

National-Level Online Article Presentation Competition

The management, staff, and students of ECP are pleased to announce that we have received a grant of ₹11,000 to organize a national-level online article presentation competition held on September 4, 2024, sponsored by Academic Decipher, Mumbai. The program was a great success, and on behalf of the management and APTI, certificates and mementos were presented to the faculty members involved in the program:

1. Program Convener: Dr. R. Sambathkumar, Principal, Erode College of Pharmacy

2. Organizing Secretary: Dr. C. Kannan, Associate Professor, Department of Pharmacy Practice, ECP

3. Organizing Secretary: Mr. S. Radhakrishnan, Assistant Professor, Department of Pharmaceutics

4. Online Article Evaluator: Dr. V. S. Saravanan, Vice Principal, Erode College of Pharmacy

5. Online Article Evaluator: Dr. V. Rajesh, Head of the Department of Pharmacology

On behalf of the management and APTI - TN Branch, we extend our sincere gratitude to our external evaluators for their valuable time and contributions to the online article competition.

Two-Day Hands-On Training Program

We are pleased to inform you that Dr. Navaneetha Krishnan, one of our esteemed faculty members, along with three of our Pharm.D interns, actively participated in a two-day hands-on training program on "Mastering Pharmaceutical Care." The program was organized by the Sri Ramakrishna Institute of Paramedical Sciences College of Pharmacy, Coimbatore, and held from October 25–26, 2024.

On the first day, participants engaged in a series of informative sessions. The training began with an in-depth session on prescription monitoring, where attendees learned to identify potential medication-related issues and ensure safe prescribing practices. This was followed by a practical session on using Lexicomp software to answer drug information queries, equipping participants with essential skills to access critical drug information swiftly. Additional sessions covered dose adjustments, emphasizing the importance of tailoring medication regimens to individual patient needs, and patient medication history and counseling, highlighting the pharmacist's role in providing comprehensive medication reviews and patient education.

On the second day, participants explored the Antibiotic Stewardship Program, gaining insights into its significance in combating antibiotic resistance and promoting appropriate antibiotic use. A session on IV incompatibility provided valuable knowledge on identifying and managing potential risks associated with intravenous therapies. The day also included discussions on adverse drug reactions (ADR), enriching participants' understanding of managing and mitigating these events.

Our faculty member and students acquired invaluable skills and knowledge during this two-day session. On behalf of ECP, we extend our heartfelt gratitude to Dr. T. K. Ravi, Principal, Dr. Sriram, HOD, and the pharmacy practice faculty members for organizing these enriching sessions for our Pharm.D and pharmacy practice students.

World Diabetes Day Celebration at The Erode College of Pharmacy

The Department of Pharmacology at The Erode College of Pharmacy, Erode, organized a meaningful World Diabetes Day celebration on 18th November 2024. The event, held from 11:30 AM to 12:30 PM, aimed to raise awareness about diabetes among the college's students and staff. This initiative was driven by Pharm D second- and third-year students, showcasing their commitment to public health education and advocacy.

The program began with an informative session where students highlighted the significance of World Diabetes Day. The theme for this year was elaborated upon, focusing on the importance of understanding, preventing, and managing diabetes. The event underscored the need for lifestyle changes, regular health check-ups, and awareness about the complications of diabetes.

A series of engaging activities were conducted to effectively communicate these messages. Educational presentations detailed the types of diabetes, risk factors, symptoms, and preventive measures. Students emphasized the importance of balanced nutrition, physical activity, and regular monitoring of blood sugar levels.

Interactive segments allowed the attendees to actively participate and gain deeper insights into diabetes management. The students demonstrated techniques for checking blood glucose levels and provided tips on maintaining a healthy diet. Additionally, real-life case studies and examples were discussed to make the subject relatable and comprehensible.

Visual aids, including posters and pamphlets prepared by the students, added an impactful dimension to the event. These materials were strategically displayed to disseminate information effectively. The creative efforts of the students were evident in the vibrant and educational content presented.

The session concluded with an open forum where students and staff had the opportunity to ask questions and clarify doubts regarding diabetes. The Pharm D students, guided by the faculty, answered these queries, ensuring the audience left with a clearer understanding of the disease.

Overall, the World Diabetes Day celebration at The Erode College of Pharmacy was a resounding success. It not only fostered awareness about diabetes but also highlighted the proactive role of future pharmacists in addressing public health challenges. By empowering students and staff with knowledge, the event exemplified the college's dedication to fostering health literacy within its community.